LV12375B - 1- (3-AMINOINDADAZOL-5-IL) -FENILMETIL) - CYCLIC UREA SUITABLE AS HIV PROTEAS INHIBITORS - Google Patents

1- (3-AMINOINDADAZOL-5-IL) -FENILMETIL) - CYCLIC UREA SUITABLE AS HIV PROTEAS INHIBITORS Download PDF

Info

Publication number: LV12375B
Authority: LV; Latvia
Prior art keywords: compound; formula; hiv; quot; reverse transcriptase
Prior art date: 1996-11-08

Application number

LVP-99-76A

Other languages

English (en)

Latvian (lv)

Other versions

LV12375A (lv

Inventor

James David Rodgers

Robert Frank Kaltenbach, Iii

Original Assignee

Dupont Pharmaceuticals Company

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-11-08

Filing date

1999-04-29

Publication date

2000-04-20

1999-04-29 Application filed by Dupont Pharmaceuticals Company filed Critical Dupont Pharmaceuticals Company

1999-11-20 Publication of LV12375A publication Critical patent/LV12375A/xx

2000-04-20 Publication of LV12375B publication Critical patent/LV12375B/en

Links

239000004030 hiv protease inhibitor Substances 0.000 title claims description 11
235000013877 carbamide Nutrition 0.000 title description 7
150000001875 compounds Chemical class 0.000 claims abstract description 123
150000003839 salts Chemical group 0.000 claims abstract description 28
238000000034 method Methods 0.000 claims abstract description 24
239000000651 prodrug Substances 0.000 claims abstract description 21
229940002612 prodrug Drugs 0.000 claims abstract description 21
239000008194 pharmaceutical composition Substances 0.000 claims abstract description 8
241000725303 Human immunodeficiency virus Species 0.000 claims description 26
239000003419 rna directed dna polymerase inhibitor Substances 0.000 claims description 21
239000000137 peptide hydrolase inhibitor Substances 0.000 claims description 18
239000000203 mixture Substances 0.000 claims description 16
208000031886 HIV Infections Diseases 0.000 claims description 15
208000037357 HIV infectious disease Diseases 0.000 claims description 15
208000033519 human immunodeficiency virus infectious disease Diseases 0.000 claims description 15
208000015181 infectious disease Diseases 0.000 claims description 15
238000011282 treatment Methods 0.000 claims description 15
CBVCZFGXHXORBI-PXQQMZJSSA-N indinavir Chemical compound C([C@H](N(CC1)C[C@@H](O)C[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H]2C3=CC=CC=C3C[C@H]2O)C(=O)NC(C)(C)C)N1CC1=CC=CN=C1 CBVCZFGXHXORBI-PXQQMZJSSA-N 0.000 claims description 12
229960001936 indinavir Drugs 0.000 claims description 11
229940124158 Protease/peptidase inhibitor Drugs 0.000 claims description 10
108010078851 HIV Reverse Transcriptase Proteins 0.000 claims description 9
229960000311 ritonavir Drugs 0.000 claims description 9
NCDNCNXCDXHOMX-XGKFQTDJSA-N ritonavir Chemical compound N([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1SC=NC=1)CC=1C=CC=CC=1)C(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-XGKFQTDJSA-N 0.000 claims description 9
229940122313 Nucleoside reverse transcriptase inhibitor Drugs 0.000 claims description 8
NCDNCNXCDXHOMX-UHFFFAOYSA-N Ritonavir Natural products C=1C=CC=CC=1CC(NC(=O)OCC=1SC=NC=1)C(O)CC(CC=1C=CC=CC=1)NC(=O)C(C(C)C)NC(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-UHFFFAOYSA-N 0.000 claims description 8
239000003937 drug carrier Substances 0.000 claims description 7
229960001852 saquinavir Drugs 0.000 claims description 7
QWAXKHKRTORLEM-UGJKXSETSA-N saquinavir Chemical group C([C@@H]([C@H](O)CN1C[C@H]2CCCC[C@H]2C[C@H]1C(=O)NC(C)(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)C=1N=C2C=CC=CC2=CC=1)C1=CC=CC=C1 QWAXKHKRTORLEM-UGJKXSETSA-N 0.000 claims description 7
239000003814 drug Substances 0.000 claims description 6
QAGYKUNXZHXKMR-HKWSIXNMSA-N nelfinavir Chemical compound CC1=C(O)C=CC=C1C(=O)N[C@H]([C@H](O)CN1[C@@H](C[C@@H]2CCCC[C@@H]2C1)C(=O)NC(C)(C)C)CSC1=CC=CC=C1 QAGYKUNXZHXKMR-HKWSIXNMSA-N 0.000 claims description 6
QAGYKUNXZHXKMR-UHFFFAOYSA-N CPD000469186 Natural products CC1=C(O)C=CC=C1C(=O)NC(C(O)CN1C(CC2CCCCC2C1)C(=O)NC(C)(C)C)CSC1=CC=CC=C1 QAGYKUNXZHXKMR-UHFFFAOYSA-N 0.000 claims description 5
YMARZQAQMVYCKC-OEMFJLHTSA-N amprenavir Chemical compound C([C@@H]([C@H](O)CN(CC(C)C)S(=O)(=O)C=1C=CC(N)=CC=1)NC(=O)O[C@@H]1COCC1)C1=CC=CC=C1 YMARZQAQMVYCKC-OEMFJLHTSA-N 0.000 claims description 5
238000004519 manufacturing process Methods 0.000 claims description 5
229960000884 nelfinavir Drugs 0.000 claims description 5
BEUUJDAEPJZWHM-COROXYKFSA-N tert-butyl n-[(2s,3s,5r)-3-hydroxy-6-[[(2s)-1-(2-methoxyethylamino)-3-methyl-1-oxobutan-2-yl]amino]-6-oxo-1-phenyl-5-[(2,3,4-trimethoxyphenyl)methyl]hexan-2-yl]carbamate Chemical compound C([C@@H]([C@@H](O)C[C@H](C(=O)N[C@H](C(=O)NCCOC)C(C)C)CC=1C(=C(OC)C(OC)=CC=1)OC)NC(=O)OC(C)(C)C)C1=CC=CC=C1 BEUUJDAEPJZWHM-COROXYKFSA-N 0.000 claims description 5
VCYQENLVFRTJIC-UHFFFAOYSA-N 4-cyano-n-[3-[cyclopropyl-(4-hydroxy-2-oxo-5,6,7,8,9,10-hexahydrocycloocta[b]pyran-3-yl)methyl]phenyl]benzenesulfonamide Chemical compound OC=1C=2CCCCCCC=2OC(=O)C=1C(C=1C=C(NS(=O)(=O)C=2C=CC(=CC=2)C#N)C=CC=1)C1CC1 VCYQENLVFRTJIC-UHFFFAOYSA-N 0.000 claims description 4
NJBBLOIWMSYVCQ-VZTVMPNDSA-N Kynostatin 272 Chemical compound C([C@H](NC(=O)[C@@H](NC(=O)COC=1C2=CC=NC=C2C=CC=1)CSC)[C@H](O)C(=O)N1[C@@H](CSC1)C(=O)NC(C)(C)C)C1=CC=CC=C1 NJBBLOIWMSYVCQ-VZTVMPNDSA-N 0.000 claims description 4
108010075606 kynostatin 272 Proteins 0.000 claims description 4
LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims description 3
238000003556 assay Methods 0.000 abstract description 17
108010010369 HIV Protease Proteins 0.000 abstract description 14
239000003112 inhibitor Substances 0.000 abstract description 9
230000009385 viral infection Effects 0.000 abstract description 3
238000009007 Diagnostic Kit Methods 0.000 abstract description 2
208000036142 Viral infection Diseases 0.000 abstract 1
239000003153 chemical reaction reagent Substances 0.000 abstract 1
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 36
239000004480 active ingredient Substances 0.000 description 24
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 21
239000000523 sample Substances 0.000 description 21
239000000243 solution Substances 0.000 description 21
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 18
241000700605 Viruses Species 0.000 description 17
235000019439 ethyl acetate Nutrition 0.000 description 16
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 16
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 12
VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicon dioxide Inorganic materials O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 12
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
108091005804 Peptidases Proteins 0.000 description 11
239000004365 Protease Substances 0.000 description 11
230000000840 anti-viral effect Effects 0.000 description 11
239000002552 dosage form Substances 0.000 description 11
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 10
102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 10
239000002775 capsule Substances 0.000 description 10
210000002845 virion Anatomy 0.000 description 10
102100034343 Integrase Human genes 0.000 description 9
108010092799 RNA-directed DNA polymerase Proteins 0.000 description 9
239000003826 tablet Substances 0.000 description 9
239000012267 brine Substances 0.000 description 8
229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 8
230000002829 reductive effect Effects 0.000 description 8
HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 8
108020004414 DNA Proteins 0.000 description 7
-1 cyclic ureas Chemical class 0.000 description 7
230000000694 effects Effects 0.000 description 7
238000009396 hybridization Methods 0.000 description 7
239000010410 layer Substances 0.000 description 7
239000003921 oil Substances 0.000 description 7
235000019198 oils Nutrition 0.000 description 7
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
238000005481 NMR spectroscopy Methods 0.000 description 6
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
108010090804 Streptavidin Proteins 0.000 description 6
WREGKURFCTUGRC-POYBYMJQSA-N Zalcitabine Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](CO)CC1 WREGKURFCTUGRC-POYBYMJQSA-N 0.000 description 6
238000006243 chemical reaction Methods 0.000 description 6
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
239000000741 silica gel Substances 0.000 description 6
229910002027 silica gel Inorganic materials 0.000 description 6
239000011780 sodium chloride Substances 0.000 description 6
239000000725 suspension Substances 0.000 description 6
ZMGMDXCADSRNCX-UHFFFAOYSA-N 5,6-dihydroxy-1,3-diazepan-2-one Chemical compound OC1CNC(=O)NCC1O ZMGMDXCADSRNCX-UHFFFAOYSA-N 0.000 description 5
108091003079 Bovine Serum Albumin Proteins 0.000 description 5
241000282414 Homo sapiens Species 0.000 description 5
238000011156 evaluation Methods 0.000 description 5
239000012894 fetal calf serum Substances 0.000 description 5
230000012010 growth Effects 0.000 description 5
238000000338 in vitro Methods 0.000 description 5
230000002401 inhibitory effect Effects 0.000 description 5
239000002609 medium Substances 0.000 description 5
239000012044 organic layer Substances 0.000 description 5
239000002243 precursor Substances 0.000 description 5
238000002360 preparation method Methods 0.000 description 5
239000000047 product Substances 0.000 description 5
239000011541 reaction mixture Substances 0.000 description 5
239000002904 solvent Substances 0.000 description 5
YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
QPFMBZIOSGYJDE-UHFFFAOYSA-N 1,1,2,2-tetrachloroethane Chemical compound ClC(Cl)C(Cl)Cl QPFMBZIOSGYJDE-UHFFFAOYSA-N 0.000 description 4
102000003886 Glycoproteins Human genes 0.000 description 4
108090000288 Glycoproteins Proteins 0.000 description 4
108010076039 Polyproteins Proteins 0.000 description 4
XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 4
239000001913 cellulose Substances 0.000 description 4
229920002678 cellulose Polymers 0.000 description 4
239000013066 combination product Substances 0.000 description 4
229940127555 combination product Drugs 0.000 description 4
230000000295 complement effect Effects 0.000 description 4
229940125904 compound 1 Drugs 0.000 description 4
238000010790 dilution Methods 0.000 description 4
239000012895 dilution Substances 0.000 description 4
201000010099 disease Diseases 0.000 description 4
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
238000009472 formulation Methods 0.000 description 4
230000005764 inhibitory process Effects 0.000 description 4
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
NQDJXKOVJZTUJA-UHFFFAOYSA-N nevirapine Chemical compound C12=NC=CC=C2C(=O)NC=2C(C)=CC=NC=2N1C1CC1 NQDJXKOVJZTUJA-UHFFFAOYSA-N 0.000 description 4
239000002777 nucleoside Substances 0.000 description 4
150000003833 nucleoside derivatives Chemical class 0.000 description 4
125000001037 p-tolyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 description 4
230000001177 retroviral effect Effects 0.000 description 4
239000007787 solid Substances 0.000 description 4
230000001225 therapeutic effect Effects 0.000 description 4
YDTDKKULPWTHRV-UHFFFAOYSA-N 1H-indazol-3-amine Chemical compound C1=CC=C2C(N)=NNC2=C1 YDTDKKULPWTHRV-UHFFFAOYSA-N 0.000 description 3
102000053602 DNA Human genes 0.000 description 3
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 3
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
239000002253 acid Substances 0.000 description 3
125000004429 atom Chemical group 0.000 description 3
239000002585 base Substances 0.000 description 3
229960002685 biotin Drugs 0.000 description 3
239000011616 biotin Substances 0.000 description 3
239000000969 carrier Substances 0.000 description 3
238000000262 chemical ionisation mass spectrometry Methods 0.000 description 3
238000004587 chromatography analysis Methods 0.000 description 3
238000000576 coating method Methods 0.000 description 3
210000001035 gastrointestinal tract Anatomy 0.000 description 3
125000004435 hydrogen atom Chemical group [H]* 0.000 description 3
239000008101 lactose Substances 0.000 description 3
150000007522 mineralic acids Chemical class 0.000 description 3
231100000252 nontoxic Toxicity 0.000 description 3
230000003000 nontoxic effect Effects 0.000 description 3
239000013612 plasmid Substances 0.000 description 3
230000008569 process Effects 0.000 description 3
230000010076 replication Effects 0.000 description 3
238000003756 stirring Methods 0.000 description 3
208000024891 symptom Diseases 0.000 description 3
241001430294 unidentified retrovirus Species 0.000 description 3
238000005160 1H NMR spectroscopy Methods 0.000 description 2
GUUKPGIJZYZERR-UHFFFAOYSA-N 5-(bromomethyl)-2-fluorobenzonitrile Chemical compound FC1=CC=C(CBr)C=C1C#N GUUKPGIJZYZERR-UHFFFAOYSA-N 0.000 description 2
206010001513 AIDS related complex Diseases 0.000 description 2
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
102000002260 Alkaline Phosphatase Human genes 0.000 description 2
108020004774 Alkaline Phosphatase Proteins 0.000 description 2
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
210000004366 CD4-positive T-lymphocyte Anatomy 0.000 description 2
OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 2
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
102000004190 Enzymes Human genes 0.000 description 2
108090000790 Enzymes Proteins 0.000 description 2
ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
108010010803 Gelatin Proteins 0.000 description 2
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
108091034117 Oligonucleotide Proteins 0.000 description 2
208000001388 Opportunistic Infections Diseases 0.000 description 2
URLKBWYHVLBVBO-UHFFFAOYSA-N Para-Xylene Chemical group CC1=CC=C(C)C=C1 URLKBWYHVLBVBO-UHFFFAOYSA-N 0.000 description 2
239000012980 RPMI-1640 medium Substances 0.000 description 2
229920002472 Starch Polymers 0.000 description 2
230000002378 acidificating effect Effects 0.000 description 2
125000003277 amino group Chemical group 0.000 description 2
AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 2
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
235000020958 biotin Nutrition 0.000 description 2
210000001124 body fluid Anatomy 0.000 description 2
239000010839 body fluid Substances 0.000 description 2
239000000872 buffer Substances 0.000 description 2
OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
239000011248 coating agent Substances 0.000 description 2
239000007891 compressed tablet Substances 0.000 description 2
150000004985 diamines Chemical class 0.000 description 2
229940079593 drug Drugs 0.000 description 2
150000002148 esters Chemical class 0.000 description 2
239000012530 fluid Substances 0.000 description 2
239000006260 foam Substances 0.000 description 2
125000000524 functional group Chemical group 0.000 description 2
239000008273 gelatin Substances 0.000 description 2
229920000159 gelatin Polymers 0.000 description 2
239000007903 gelatin capsule Substances 0.000 description 2
235000019322 gelatine Nutrition 0.000 description 2
235000011852 gelatine desserts Nutrition 0.000 description 2
230000014509 gene expression Effects 0.000 description 2
239000011521 glass Substances 0.000 description 2
239000008187 granular material Substances 0.000 description 2
239000001963 growth medium Substances 0.000 description 2
ZJYYHGLJYGJLLN-UHFFFAOYSA-N guanidinium thiocyanate Chemical compound SC#N.NC(N)=N ZJYYHGLJYGJLLN-UHFFFAOYSA-N 0.000 description 2
229940093915 gynecological organic acid Drugs 0.000 description 2
OAKJQQAXSVQMHS-UHFFFAOYSA-N hydrazine Substances NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 2
150000007857 hydrazones Chemical class 0.000 description 2
239000001257 hydrogen Substances 0.000 description 2
229910052739 hydrogen Inorganic materials 0.000 description 2
125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
210000000987 immune system Anatomy 0.000 description 2
230000001506 immunosuppresive effect Effects 0.000 description 2
238000001727 in vivo Methods 0.000 description 2
230000002458 infectious effect Effects 0.000 description 2
239000002054 inoculum Substances 0.000 description 2
210000000936 intestine Anatomy 0.000 description 2
239000008297 liquid dosage form Substances 0.000 description 2
239000006166 lysate Substances 0.000 description 2
235000019359 magnesium stearate Nutrition 0.000 description 2
229910052943 magnesium sulfate Inorganic materials 0.000 description 2
239000000463 material Substances 0.000 description 2
238000002156 mixing Methods 0.000 description 2
238000012986 modification Methods 0.000 description 2
230000004048 modification Effects 0.000 description 2
150000007524 organic acids Chemical class 0.000 description 2
235000005985 organic acids Nutrition 0.000 description 2
LXCFILQKKLGQFO-UHFFFAOYSA-N p-hydroxybenzoic acid methyl ester Natural products COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
239000003182 parenteral nutrition solution Substances 0.000 description 2
239000002245 particle Substances 0.000 description 2
230000003285 pharmacodynamic effect Effects 0.000 description 2
239000002953 phosphate buffered saline Substances 0.000 description 2
239000000902 placebo Substances 0.000 description 2
229940068196 placebo Drugs 0.000 description 2
229920000642 polymer Polymers 0.000 description 2
LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 2
239000000843 powder Substances 0.000 description 2
238000012545 processing Methods 0.000 description 2
QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
230000001681 protective effect Effects 0.000 description 2
238000010992 reflux Methods 0.000 description 2
238000011160 research Methods 0.000 description 2
229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
230000000087 stabilizing effect Effects 0.000 description 2
239000008107 starch Substances 0.000 description 2
235000019698 starch Nutrition 0.000 description 2
239000000126 substance Substances 0.000 description 2
238000013268 sustained release Methods 0.000 description 2
239000012730 sustained-release form Substances 0.000 description 2
238000003786 synthesis reaction Methods 0.000 description 2
238000012360 testing method Methods 0.000 description 2
231100000419 toxicity Toxicity 0.000 description 2
230000001988 toxicity Effects 0.000 description 2
238000013518 transcription Methods 0.000 description 2
230000035897 transcription Effects 0.000 description 2
150000003672 ureas Chemical class 0.000 description 2
NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 description 1
BCHIXGBGRHLSBE-UHFFFAOYSA-N (4-methyl-2-oxochromen-7-yl) dihydrogen phosphate Chemical compound C1=C(OP(O)(O)=O)C=CC2=C1OC(=O)C=C2C BCHIXGBGRHLSBE-UHFFFAOYSA-N 0.000 description 1
MPOLZPRZMBTQLP-XPGKHFPBSA-N (4r,5s,6s,7r)-4,7-dibenzyl-1,3-bis(2-ethoxyethyl)-5,6-dihydroxy-1,3-diazepan-2-one Chemical compound C([C@H]1N(C(N(CCOCC)[C@H](CC=2C=CC=CC=2)[C@H](O)[C@H]1O)=O)CCOCC)C1=CC=CC=C1 MPOLZPRZMBTQLP-XPGKHFPBSA-N 0.000 description 1
WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 1
ANUSGJXVCFPWMQ-UHFFFAOYSA-N 1-(2-phenylethyl)-3-(1,3-thiazol-2-yl)thiourea Chemical compound N=1C=CSC=1NC(=S)NCCC1=CC=CC=C1 ANUSGJXVCFPWMQ-UHFFFAOYSA-N 0.000 description 1
URDCARMUOSMFFI-UHFFFAOYSA-N 2-[2-[bis(carboxymethyl)amino]ethyl-(2-hydroxyethyl)amino]acetic acid Chemical compound OCCN(CC(O)=O)CCN(CC(O)=O)CC(O)=O URDCARMUOSMFFI-UHFFFAOYSA-N 0.000 description 1
125000005273 2-acetoxybenzoic acid group Chemical group 0.000 description 1
WHFRDXVXYMGAJD-UHFFFAOYSA-N 3-[(4,7-dichloro-1,3-benzoxazol-2-yl)methylamino]-5-ethyl-6-methyl-1h-pyridin-2-one Chemical compound O=C1NC(C)=C(CC)C=C1NCC1=NC2=C(Cl)C=CC(Cl)=C2O1 WHFRDXVXYMGAJD-UHFFFAOYSA-N 0.000 description 1
LELMRLNNAOPAPI-UFLZEWODSA-N 5-[(3as,4s,6ar)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoic acid;aminophosphonous acid Chemical compound NP(O)O.N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 LELMRLNNAOPAPI-UFLZEWODSA-N 0.000 description 1
108010017640 Aspartic Acid Proteases Proteins 0.000 description 1
102000004580 Aspartic Acid Proteases Human genes 0.000 description 1
COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
206010059866 Drug resistance Diseases 0.000 description 1
238000002965 ELISA Methods 0.000 description 1
OTMSDBZUPAUEDD-UHFFFAOYSA-N Ethane Chemical compound CC OTMSDBZUPAUEDD-UHFFFAOYSA-N 0.000 description 1
BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
101710177291 Gag polyprotein Proteins 0.000 description 1
CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
229930182566 Gentamicin Natural products 0.000 description 1
229940122440 HIV protease inhibitor Drugs 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
206010062016 Immunosuppression Diseases 0.000 description 1
229930194542 Keto Natural products 0.000 description 1
ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
229930182816 L-glutamine Natural products 0.000 description 1
201000010743 Lambert-Eaton myasthenic syndrome Diseases 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
241000404146 Minois Species 0.000 description 1
FFDGPVCHZBVARC-UHFFFAOYSA-N N,N-dimethylglycine Chemical class CN(C)CC(O)=O FFDGPVCHZBVARC-UHFFFAOYSA-N 0.000 description 1
235000019502 Orange oil Nutrition 0.000 description 1
102000035195 Peptidases Human genes 0.000 description 1
229920001213 Polysorbate 20 Polymers 0.000 description 1
239000007868 Raney catalyst Substances 0.000 description 1
NPXOKRUENSOPAO-UHFFFAOYSA-N Raney nickel Chemical compound [Al].[Ni] NPXOKRUENSOPAO-UHFFFAOYSA-N 0.000 description 1
229910000564 Raney nickel Inorganic materials 0.000 description 1
102000006382 Ribonucleases Human genes 0.000 description 1
108010083644 Ribonucleases Proteins 0.000 description 1
108020004682 Single-Stranded DNA Proteins 0.000 description 1
DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
235000021355 Stearic acid Nutrition 0.000 description 1
101150057615 Syn gene Proteins 0.000 description 1
101710137500 T7 RNA polymerase Proteins 0.000 description 1
239000007983 Tris buffer Substances 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
230000009471 action Effects 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
230000000996 additive effect Effects 0.000 description 1
239000003513 alkali Substances 0.000 description 1
208000026935 allergic disease Diseases 0.000 description 1
150000001412 amines Chemical class 0.000 description 1
125000004103 aminoalkyl group Chemical group 0.000 description 1
230000003064 anti-oxidating effect Effects 0.000 description 1
239000003443 antiviral agent Substances 0.000 description 1
238000013459 approach Methods 0.000 description 1
239000007900 aqueous suspension Substances 0.000 description 1
235000010323 ascorbic acid Nutrition 0.000 description 1
239000011668 ascorbic acid Substances 0.000 description 1
229960005070 ascorbic acid Drugs 0.000 description 1
238000013096 assay test Methods 0.000 description 1
230000004888 barrier function Effects 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
230000008901 benefit Effects 0.000 description 1
229960000686 benzalkonium chloride Drugs 0.000 description 1
150000001558 benzoic acid derivatives Chemical class 0.000 description 1
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
230000000903 blocking effect Effects 0.000 description 1
230000037396 body weight Effects 0.000 description 1
239000004202 carbamide Substances 0.000 description 1
229910052799 carbon Inorganic materials 0.000 description 1
125000004432 carbon atom Chemical group C* 0.000 description 1
PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 1
150000001735 carboxylic acids Chemical class 0.000 description 1
210000004027 cell Anatomy 0.000 description 1
229960004926 chlorobutanol Drugs 0.000 description 1
HEDRZPFGACZZDS-UHFFFAOYSA-N chloroform Substances ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 1
238000003776 cleavage reaction Methods 0.000 description 1
229940075614 colloidal silicon dioxide Drugs 0.000 description 1
239000012230 colorless oil Substances 0.000 description 1
238000002648 combination therapy Methods 0.000 description 1
229940125782 compound 2 Drugs 0.000 description 1
229940125898 compound 5 Drugs 0.000 description 1
235000012343 cottonseed oil Nutrition 0.000 description 1
239000002385 cottonseed oil Substances 0.000 description 1
125000004122 cyclic group Chemical group 0.000 description 1
231100000135 cytotoxicity Toxicity 0.000 description 1
230000003013 cytotoxicity Effects 0.000 description 1
230000034994 death Effects 0.000 description 1
230000007423 decrease Effects 0.000 description 1
239000008367 deionised water Substances 0.000 description 1
229910021641 deionized water Inorganic materials 0.000 description 1
238000001514 detection method Methods 0.000 description 1
239000008121 dextrose Substances 0.000 description 1
ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
238000006073 displacement reaction Methods 0.000 description 1
239000012153 distilled water Substances 0.000 description 1
239000002702 enteric coating Substances 0.000 description 1
238000009505 enteric coating Methods 0.000 description 1
150000002118 epoxides Chemical class 0.000 description 1
238000000605 extraction Methods 0.000 description 1
238000011049 filling Methods 0.000 description 1
125000001207 fluorophenyl group Chemical group 0.000 description 1
230000004927 fusion Effects 0.000 description 1
108010027225 gag-pol Fusion Proteins Proteins 0.000 description 1
230000002068 genetic effect Effects 0.000 description 1
239000008103 glucose Substances 0.000 description 1
150000002334 glycols Chemical class 0.000 description 1
238000005469 granulation Methods 0.000 description 1
230000003179 granulation Effects 0.000 description 1
230000036541 health Effects 0.000 description 1
238000004128 high performance liquid chromatography Methods 0.000 description 1
210000005260 human cell Anatomy 0.000 description 1
IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine monohydrate Substances O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 1
125000004356 hydroxy functional group Chemical group O* 0.000 description 1
UWYVPFMHMJIBHE-OWOJBTEDSA-N hydroxymaleic acid group Chemical group O/C(/C(=O)O)=C/C(=O)O UWYVPFMHMJIBHE-OWOJBTEDSA-N 0.000 description 1
239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
230000028993 immune response Effects 0.000 description 1
230000000899 immune system response Effects 0.000 description 1
239000002955 immunomodulating agent Substances 0.000 description 1
229940121354 immunomodulator Drugs 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
229910052500 inorganic mineral Inorganic materials 0.000 description 1
230000003993 interaction Effects 0.000 description 1
230000007794 irritation Effects 0.000 description 1
238000002955 isolation Methods 0.000 description 1
125000000468 ketone group Chemical group 0.000 description 1
230000002147 killing effect Effects 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
WGOPGODQLGJZGL-UHFFFAOYSA-N lithium;butane Chemical compound [Li+].CC[CH-]C WGOPGODQLGJZGL-UHFFFAOYSA-N 0.000 description 1
210000004698 lymphocyte Anatomy 0.000 description 1
210000002540 macrophage Anatomy 0.000 description 1
239000011777 magnesium Substances 0.000 description 1
229910052749 magnesium Inorganic materials 0.000 description 1
229910001629 magnesium chloride Inorganic materials 0.000 description 1
238000004949 mass spectrometry Methods 0.000 description 1
235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
229960002216 methylparaben Drugs 0.000 description 1
239000011707 mineral Substances 0.000 description 1
239000002480 mineral oil Substances 0.000 description 1
235000010446 mineral oil Nutrition 0.000 description 1
150000004682 monohydrates Chemical class 0.000 description 1
238000002703 mutagenesis Methods 0.000 description 1
231100000350 mutagenesis Toxicity 0.000 description 1
125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
229960000689 nevirapine Drugs 0.000 description 1
150000002825 nitriles Chemical class 0.000 description 1
108020004707 nucleic acids Proteins 0.000 description 1
102000039446 nucleic acids Human genes 0.000 description 1
150000007523 nucleic acids Chemical class 0.000 description 1
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
229920002113 octoxynol Polymers 0.000 description 1
239000004006 olive oil Substances 0.000 description 1
235000008390 olive oil Nutrition 0.000 description 1
239000010502 orange oil Substances 0.000 description 1
239000012074 organic phase Substances 0.000 description 1
239000003960 organic solvent Substances 0.000 description 1
235000019629 palatability Nutrition 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 1
150000003014 phosphoric acid esters Chemical class 0.000 description 1
108010089520 pol Gene Products Proteins 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
238000001556 precipitation Methods 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
230000000644 propagated effect Effects 0.000 description 1
235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
229960003415 propylparaben Drugs 0.000 description 1
235000018102 proteins Nutrition 0.000 description 1
108090000623 proteins and genes Proteins 0.000 description 1
102000004169 proteins and genes Human genes 0.000 description 1
230000002797 proteolythic effect Effects 0.000 description 1
238000003908 quality control method Methods 0.000 description 1
150000003242 quaternary ammonium salts Chemical class 0.000 description 1
WTTIBCHOELPGFK-LBPRGKRZSA-N r82150 Chemical class C1N(CC=C(C)C)[C@@H](C)CN2C(=S)NC3=CC=CC1=C32 WTTIBCHOELPGFK-LBPRGKRZSA-N 0.000 description 1
230000009467 reduction Effects 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
230000027272 reproductive process Effects 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
229920006395 saturated elastomer Polymers 0.000 description 1
230000007017 scission Effects 0.000 description 1
238000007789 sealing Methods 0.000 description 1
210000000582 semen Anatomy 0.000 description 1
238000013207 serial dilution Methods 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
239000002002 slurry Substances 0.000 description 1
239000011734 sodium Substances 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
235000010234 sodium benzoate Nutrition 0.000 description 1
239000004299 sodium benzoate Substances 0.000 description 1
229910000029 sodium carbonate Inorganic materials 0.000 description 1
239000001509 sodium citrate Substances 0.000 description 1
NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
235000010265 sodium sulphite Nutrition 0.000 description 1
239000007909 solid dosage form Substances 0.000 description 1
239000003549 soybean oil Substances 0.000 description 1
235000012424 soybean oil Nutrition 0.000 description 1
238000004611 spectroscopical analysis Methods 0.000 description 1
238000012289 standard assay Methods 0.000 description 1
239000008117 stearic acid Substances 0.000 description 1
230000001954 sterilising effect Effects 0.000 description 1
238000004659 sterilization and disinfection Methods 0.000 description 1
210000002784 stomach Anatomy 0.000 description 1
125000001424 substituent group Chemical group 0.000 description 1
238000006467 substitution reaction Methods 0.000 description 1
230000002459 sustained effect Effects 0.000 description 1
208000011580 syndromic disease Diseases 0.000 description 1
230000002195 synergetic effect Effects 0.000 description 1
239000011885 synergistic combination Substances 0.000 description 1
UEUXEKPTXMALOB-UHFFFAOYSA-J tetrasodium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O UEUXEKPTXMALOB-UHFFFAOYSA-J 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
125000003944 tolyl group Chemical group 0.000 description 1
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
MWOOGOJBHIARFG-UHFFFAOYSA-N vanillin Chemical compound COC1=CC(C=O)=CC=C1O MWOOGOJBHIARFG-UHFFFAOYSA-N 0.000 description 1
235000012141 vanillin Nutrition 0.000 description 1
FGQOOHJZONJGDT-UHFFFAOYSA-N vanillin Natural products COC1=CC(O)=CC(C=O)=C1 FGQOOHJZONJGDT-UHFFFAOYSA-N 0.000 description 1
238000010792 warming Methods 0.000 description 1
239000011534 wash buffer Substances 0.000 description 1
YZYKBQUWMPUVEN-UHFFFAOYSA-N zafuleptine Chemical compound OC(=O)CCCCCC(C(C)C)NCC1=CC=C(F)C=C1 YZYKBQUWMPUVEN-UHFFFAOYSA-N 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Virology (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Communicable Diseases (AREA)
AIDS & HIV (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Oncology (AREA)
Molecular Biology (AREA)
Tropical Medicine & Parasitology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Plural Heterocyclic Compounds (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

LVP-99-76A 1996-11-08 1999-04-29 1- (3-AMINOINDADAZOL-5-IL) -FENILMETIL) - CYCLIC UREA SUITABLE AS HIV PROTEAS INHIBITORS LV12375B (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US2974596P	1996-11-08	1996-11-08
US74710496A	1996-11-08	1996-11-08
PCT/US1997/020035 WO1998020008A1 (en)	1996-11-08	1997-11-04	1-(3-aminoindazol-5-yl)-3-phenylmethyl-cyclic ureas useful as hiv protease inhibitors

Publications (2)

Publication Number	Publication Date
LV12375A LV12375A (lv)	1999-11-20
LV12375B true LV12375B (en)	2000-04-20

Family

ID=26705293

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
LVP-99-76A LV12375B (en)	1996-11-08	1999-04-29	1- (3-AMINOINDADAZOL-5-IL) -FENILMETIL) - CYCLIC UREA SUITABLE AS HIV PROTEAS INHIBITORS

Country Status (21)

Country	Link
EP (1)	EP0937067B1 (et)
JP (1)	JP2001503428A (et)
KR (1)	KR20000053122A (et)
CN (1)	CN1235602A (et)
AT (1)	ATE244714T1 (et)
AU (1)	AU5165198A (et)
BR (1)	BR9712910A (et)
CA (1)	CA2270966A1 (et)
CZ (1)	CZ157599A3 (et)
DE (1)	DE69723456T2 (et)
EA (1)	EA199900452A1 (et)
EE (1)	EE9900188A (et)
ES (1)	ES2202645T3 (et)
HU (1)	HUP9904676A2 (et)
IL (1)	IL129727A0 (et)
LV (1)	LV12375B (et)
NO (1)	NO992228L (et)
PL (1)	PL333421A1 (et)
SI (1)	SI20074A (et)
SK (1)	SK59699A3 (et)
WO (1)	WO1998020008A1 (et)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2001518094A (ja) *	1997-03-31	2001-10-09	デュポンファーマシューティカルズカンパニー	Ｈｉｖプロテアーゼ阻害剤として有用なインダゾール−環式尿素
US7135575B2 (en)	2003-03-03	2006-11-14	Array Biopharma, Inc.	P38 inhibitors and methods of use thereof
MY151835A (en)	2006-01-31	2014-07-14	Array Biopharma Inc	Kinase inhibitors and methods of use thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5610294A (en) *	1991-10-11	1997-03-11	The Du Pont Merck Pharmaceutical Company	Substituted cyclic carbonyls and derivatives thereof useful as retroviral protease inhibitors
US5532357A (en) *	1995-06-07	1996-07-02	The Dupont Merck Pharmaceutical Company	Method for preparing N-monosubstituted and N,N'-disubstituted unsymmetrical cyclic ureas

1997
- 1997-11-04 AT AT97946494T patent/ATE244714T1/de not_active IP Right Cessation
- 1997-11-04 CZ CZ991575A patent/CZ157599A3/cs unknown
- 1997-11-04 EA EA199900452A patent/EA199900452A1/ru unknown
- 1997-11-04 EP EP97946494A patent/EP0937067B1/en not_active Expired - Lifetime
- 1997-11-04 SK SK596-99A patent/SK59699A3/sk unknown
- 1997-11-04 DE DE69723456T patent/DE69723456T2/de not_active Expired - Fee Related
- 1997-11-04 PL PL97333421A patent/PL333421A1/xx unknown
- 1997-11-04 ES ES97946494T patent/ES2202645T3/es not_active Expired - Lifetime
- 1997-11-04 BR BR9712910A patent/BR9712910A/pt not_active Application Discontinuation
- 1997-11-04 IL IL12972797A patent/IL129727A0/xx unknown
- 1997-11-04 WO PCT/US1997/020035 patent/WO1998020008A1/en not_active Application Discontinuation
- 1997-11-04 CA CA002270966A patent/CA2270966A1/en not_active Abandoned
- 1997-11-04 CN CN97199419A patent/CN1235602A/zh active Pending
- 1997-11-04 SI SI9720072A patent/SI20074A/sl unknown
- 1997-11-04 EE EEP199900188A patent/EE9900188A/et unknown
- 1997-11-04 KR KR1019990704048A patent/KR20000053122A/ko not_active Application Discontinuation
- 1997-11-04 HU HU9904676A patent/HUP9904676A2/hu unknown
- 1997-11-04 AU AU51651/98A patent/AU5165198A/en not_active Abandoned
- 1997-11-04 JP JP52168198A patent/JP2001503428A/ja active Pending
1999
- 1999-04-29 LV LVP-99-76A patent/LV12375B/en unknown
- 1999-05-07 NO NO992228A patent/NO992228L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
NO992228L (no)	1999-06-07
EP0937067A1 (en)	1999-08-25
NO992228D0 (no)	1999-05-07
BR9712910A (pt)	2000-03-21
SI20074A (sl)	2000-04-30
KR20000053122A (ko)	2000-08-25
EP0937067B1 (en)	2003-07-09
CN1235602A (zh)	1999-11-17
CZ157599A3 (cs)	1999-11-17
PL333421A1 (en)	1999-12-06
LV12375A (lv)	1999-11-20
JP2001503428A (ja)	2001-03-13
AU5165198A (en)	1998-05-29
EA199900452A1 (ru)	2000-02-28
CA2270966A1 (en)	1998-05-14
ES2202645T3 (es)	2004-04-01
EE9900188A (et)	1999-12-15
WO1998020008A1 (en)	1998-05-14
DE69723456T2 (de)	2004-05-27
HUP9904676A2 (hu)	2000-06-28
ATE244714T1 (de)	2003-07-15
DE69723456D1 (de)	2003-08-14
SK59699A3 (en)	1999-12-10
IL129727A0 (en)	2000-02-29

Publication	Publication Date	Title
US6825210B2 (en)	2004-11-30	Tricyclic compounds useful as HIV reverse transcriptase inhibitors
US5932570A (en)	1999-08-03	1-(3-aminoindazol-5-yl)-3-phenylmethyl-cyclic ureas useful as HIV protease inhibitors
US6391919B1 (en)	2002-05-21	Bis-amino acid sulfonamides containing substituted benzyl amines HIV protease inhibitors
EP0937067B1 (en)	2003-07-09	1-(3-aminoindazol-5-yl)-3-phenylmethyl-cyclic ureas useful as hiv protease inhibitors
US6313110B1 (en)	2001-11-06	Substituted 2H-1,3-diazapin-2-one useful as an HIV protease inhibitor
US6218386B1 (en)	2001-04-17	A1-(3-aminoindazol-5-yl)-3 butyl-cyclic urea useful as a HIV protease inhibitor
AU722489B2 (en)	2000-08-03	(4r,5s,6s,7r)-hexahydro-1- {5-(3-aminoinazole)methyl} -3-butyl-5,6-dihydr oxy-4,7-bis {phaenylmethyl} -2h-1,3-diazepin-2-one, its preparation and its use as HIV protease inhibitor
AU2725700A (en)	2000-08-01	Bis-amino acid sulfonamides containing n-terminally a substituted benzyl group as hiv protease inhibitors
US6562848B1 (en)	2003-05-13	Bis-amino acid sulfonamides as HIV protease inhibitors
WO2004013110A1 (en)	2004-02-12	4,4-disubstituted-3,4-dihydro-2(1h)-quinazoliniones useful as hiv reverse transcriptase inhibitors
WO2004043911A2 (en)	2004-05-27	N-cycloalkylglycines as hiv protease inhibitors
US7015214B2 (en)	2006-03-21	Cyanamide, alkoxyamino, and urea derivatives of 1,3-benzodiazepine as HIV reverse transcriptase inhibitors
MXPA99004286A (en)	2000-01-01	1-(3-aminoindazol-5-yl)-3-phenylmethyl-cyclic ureas useful as hiv protease inhibitors
HRP970586A2 (en)	1998-08-31	1-(3-aminoindazol-5-yl)-3-phenylmethyl-cyclic ureas useful as hiv protease inhibitors
MXPA99004294A (en)	2000-01-01	(4r,5s,6s,7r)-hexahydro-1- [5-(3-aminoinazole)methyl]-3-butyl-5,6-dihydroxy-4,7-bis [phaenylmethyl]-2h-1,3-diazepin-2-one, its preparation and its use as hiv protease inhibitor
MXPA01007047A (en)	2002-03-05	Bis-amino acid sulfonamides containing n-terminally a substituted benzyl group as hiv protease inhibitors
HRP970595A2 (en)	1998-08-31	1-(3-aminoindazol-5-yl)-3-butyl-cyclic urea useful as a hiv proteaze inhibitor
AU2002254652A1 (en)	2002-11-05	Tricyclic compounds useful as HIV reverse transcriptase inhibitors